Sector
PharmaceuticalsOpen
₹970.9Prev. Close
₹970.35Turnover(Lac.)
₹11,143.87Day's High
₹972.4Day's Low
₹955.8552 Week's High
₹972.5552 Week's Low
₹474.05Book Value
₹91.47Face Value
₹2Mkt Cap (₹ Cr.)
51,858.28P/E
76.68EPS
12.65Divi. Yield
0.1215 May 2025
12:00 AM
AGM
Announcement Date: 15 May, 2025
9 Oct 2025
12:00 AM
Board Meeting
Agenda : Audited Result
23 Oct 2025
12:00 AM
Dividend
Dividend Amount: 0.8
Record Date: 31 Oct, 2025
Finished Dosage Formulations (FDF) business also saw a 27% growth, while the Generics business saw moderate growth of 5%
The said transaction falls under related party transactions. However, the same is being carried at arm’s length price.
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 107.85 | 107.79 | 107.73 | 107.47 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 4,456.1 | 4,099.26 | 3,949.09 | 3,280.74 |
Net Worth | 4,563.95 | 4,207.05 | 4,056.82 | 3,388.21 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 4,707.04 | 4,768.72 | 2,797.33 | 2,026.84 |
yoy growth (%) | -1.29 | 70.47 | 38.01 | 7.13 |
Raw materials | -2,208.56 | -2,175.13 | -1,402.54 | -1,056.4 |
As % of sales | 46.92 | 45.61 | 50.13 | 52.12 |
Employee costs | -445.14 | -401.88 | -323.99 | -238.14 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 975.41 | 1,274.63 | 304.48 | 240.9 |
Depreciation | -235.48 | -196.64 | -183.85 | -121.23 |
Tax paid | -225.32 | -318.52 | -37.43 | -67.76 |
Working capital | 145.83 | 684.91 | 246.73 | 42.81 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -1.29 | 70.47 | 38.01 | 7.13 |
Op profit growth | -14.88 | 164.78 | 39.5 | -1.22 |
EBIT growth | -20.08 | 241.8 | 23.97 | -7.49 |
Net profit growth | -21.54 | 258.03 | 54.23 | -13.41 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 5,553.96 | 5,040.83 | 6,040.55 | 4,935.57 | 4,813.51 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 5,553.96 | 5,040.83 | 6,040.55 | 4,935.57 | 4,813.51 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 75.1 | 26.34 | 6 | 15.3 | 23.66 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,703.4 | 82.06 | 4,08,750.71 | 753.53 | 0.94 | 5,566.68 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,655 | 75.61 | 1,76,633.5 | 557 | 0.45 | 2,357 | 561.08 |
Cipla Ltd CIPLA | 1,540.1 | 23.94 | 1,24,437.16 | 1,210.53 | 1.04 | 4,495.16 | 411.56 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,602.4 | 61.3 | 1,21,865.35 | 551 | 0.17 | 2,567 | 224.34 |
Mankind Pharma Ltd MANKIND | 2,446.6 | 55.79 | 1,00,950.41 | 412.76 | 0 | 2,541.36 | 354.69 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Whole Time Director & Chief Executive Officer
CHAVA SATYANARAYANA
Whole Time Director & Chief Financial Officer
VENKATA RAVI KUMAR VANTARAM
Independent Director
Aruna Bhinge
Independent Director
Rajesh Koshy Chandy
Chairman & Independent Director
Ravindranath Kancherla
Executive Director
Venkata Lakshmana Rao Chunduru
Independent Director
Karnam Sekar
Executive Director
KRISHNA CHAITANYA CHAVA
Vice President & Company Secretary
G Venkateswar Reddy
Executive Director
Soumya Chava
Independent Director
Ramesh Subrahmanian
Plot No 21 Jawaharlal Nehru,
Pharma City Parawada,
Andhra Pradesh - 531021
Tel: 91-891-3061222
Website: http://www.lauruslabs.com
Email: secretarial@lauruslabs.com; info@lauruslabs.com
Karvy Selenium Tow-B,
31&32 Financial Dist, Nanakramguda,
Hyderabad-500032
Tel: 91-40-67162222
Website: www.kfintech.com
Email: einward.ris@kfintech.com
Summary
Laurus Labs Limited was originally incorporated as Laurus Labs Private Limited on September 19, 2005 at Hyderabad, Andhra Pradesh, India as a private limited company. The company was subsequently conv...
Read More
Reports by Laurus Labs Ltd
What is the Laurus Labs Ltd share price today?
What is the Market Cap of Laurus Labs Ltd?
What is the PE and PB ratio of Laurus Labs Ltd?
What is the 52 Week High and Low of Laurus Labs Ltd?
What is the CAGR of Laurus Labs Ltd?
What is the shareholding pattern of Laurus Labs Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
